Anti-Drug Antibody Reagent Development

Current industry best practices and FDA guidelines urge therapeutic antibody developers to use affinity-purified polyclonal antibodies in anti-drug assays for immunogenicity studies as well as controls for ongoing drug monitoring.

MBS delivers sensitive and specific positive ADA controls through:

  • Dedicated project management of polyclonal antibody development
  • Goal-driven immunization strategies
  • Advanced, application-specific screening of serum samples
  • Custom affinity purification
  • Lifetime supply of antibody generated within 5 months

ADA Bridging Assays









Learn More about Polyclonal Antibody Development


Read the MBS Biology of Antibodies Blog on the Detection of Therapeutic Antibodies

The post Anti-Drug Antibody Reagent Development appeared first on Maine Biotechnology.


About the Author: Biotech Today

You might like